Also listed on Tarveda Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Lapsed Oct 4, 2026 on the fee record · Low confidence
20-year base term ends Jun 30, 2035
First maintenance fee unpaid; grace period ended.
Jun 30, 2015
Oct 4, 2026
Oct 4, 2022
Jun 30, 2035
Its term would have run to Jun 30, 2035: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Low. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 30, 2015, when application PCT/US2015/038569, the earliest non-provisional in its chain, was filed (this one was filed Feb 18, 2020); a parent in its chain could not be resolved (the next row) | Jun 30, 2035 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,750,818) | resolves to Jun 30, 2035, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | lapsed Oct 4, 2026 | High confidence |
| Further caveats on record | The record names parents not resolved: PCTUS2015038569, PCTUS2015038569, PCTUS2015038569 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Oct 4, 2026 | Low confidence |
This family
| Application PCT/US2015/038569 | PCT application no patent term | no patent term |
| US 9,750,818 | Lapsed on the fee record Sep 2025 | Sep 2025 |
| US 10,322,191 | Lapsed on the fee record Jun 2023 | Jun 2023 |
| US 10,624,967 | Lapsed on the fee record Apr 2024 | Apr 2024 |
| US 11,458,206 | this patent Oct 2026 | Oct 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 21, 2020 Reel 51885, frame 130 | Alargova, Rossitza G.; Bilodeau, Mark T.; Dunbar, Craig A.; Kadiyala, Sudhakar; Shinde, Rajesh R.; Lim Soo, Patrick; Sweryda-krawiec, Beata; White, Brian H.; Bazinet, Patrick Rosaire; Wooster, Richard | Blend Therapeutics, Inc. | Assignment of Assignor's Interest |
| Feb 21, 2020 Reel 51986, frame 771 | Blend Therapeutics, Inc. | Tarveda Therapeutics, Inc. | Change of Name |
| Oct 4, 2021 Reel 57988, frame 232 | Tarveda Therapeutics, Inc. | Oxford Finance LLC | Security Interest |
| Apr 25, 2022 Reel 59788, frame 518 | Tarveda Therapeutics, Inc. | Tva (ABC), LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 9,750,818, ends no earlier than this term, so it caps nothing.